AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Glucon-D maintained its leadership position with a 59% MAT market share
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Subscribe To Our Newsletter & Stay Updated